| Literature DB >> 22577389 |
Sing Yun Chang1, Karina Keogh, Jean E Lewis, Jay H Ryu, Eunhee S Yi.
Abstract
Granulomatosis with polyangiitis (Wegener's) (GPA) may mimic IgG4-related disease (IgG4-RD) on histologic examination of some biopsies, especially those from head and neck sites. IgG4 immunostain is often performed in this context for differential diagnosis with IgG4-RD. However, the prevalence of IgG4+ cells in GPA has not been explored. We examined the IgG4+ cells in 26 cases confirmed as GPA by a thorough clinical and pathologic assessment. Twenty-six biopsies consisted of 14 sinonasal/oral cavity/nasopharynx, 7 orbit/periorbital, 3 lung/pleura, 1 iliac fossa/kidney, and 1 dura specimens. Eight of 26 (31%) biopsies revealed increased IgG4+ cells (>30/HPF and >40% in IgG4+/IgG+ ratio). The IgG4+ cells and IgG4+/IgG+ ratio ranged 37-137/hpf and 44-83%, respectively. Eight biopsies with increased IgG4+ cells were from sinonasal (n = 4) or orbital/periorbital (n = 4) sites. In conclusion, increased IgG4+ cells are not uncommonly seen in sinonasal or orbital/periorbital biopsies of GPA, which could pose as a diagnostic pitfall.Entities:
Year: 2012 PMID: 22577389 PMCID: PMC3332209 DOI: 10.1155/2012/121702
Source DB: PubMed Journal: Int J Rheumatol ISSN: 1687-9260
Figure 1(a) Increased IgG4-positive cells with a high IgG4+/IgG+ ratio. (b) IgG+ cells from corresponding hotspot (immunohistochemistry, 400x original magnification).
Clinical features, immunohistochemical findings, ANCA details, and CRP level.
| Case no. | Sex | Age at Dx | Biopsy site | IgG4 average | IgG4/IgG ratio | Path Dx score | Clinical Dx (modified ACR criteria) | ANCA (+) | P-ANCA | MPO | C-ANCA | PR3 | CRP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 74 | Nasal septum | 28 | 87% | 3 | Generalized | y | n | n | y | y | High |
| 2 | F | 83 | Nasal sinus | 20 | 63% | 3 | Limited | y | n | n | y | y | High |
| 3 | M | 54 | Nasal septum | 62 | 59% | 3 | Generalized | y | n | n | y | y | High |
| 4 | F | 59 | Lung RUL RML | 27 | 28% | 3 | Limited | y | y | y | n | n | NA |
| 5 | F | 19 | Oral cavity | 6 | 19% | 3 | Generalized | y | n | n | y | y | NA |
| 6 | F | 18 | Nasal sinus | 11 | 79% | 1 | Generalized | y | y | y | n | n | NA |
| 7* | M | 47 | Orbit | 49 | 58% | 2 | Generalized | y | n | n | y | y | High* |
| 8* | M | 47 | Nasal septum | 4 | 19% | 1 | Generalized | y | n | n | y | y | * |
| 9** | F | 31 | Lung, left, pneumonectomy | 16 | 33% | 3 | Generalized | y | n | n | y | y | NA** |
| 10** | F | 31 | Kidney | 26 | 39% | 3 | Generalized | y | n | n | y | y | ** |
| 11 | M | 52 | Bilateral orbital mass | 1 | 1% | 3 | Generalized | n | n | n | n | n | High |
| 12 | M | 31 | Nasal cavity | 13 | 32% | 2 | Limited | y | n | n | y | y | High |
| 13 | F | 16 | Nasal cavity | 1 | 7% | 1 | Limited | y | n | n | y | y | High |
| 14 | F | 47 | Orbital soft tissue | 24 | 53% | 2 | Generalized | y | y | n | y | y | High |
| 15 | F | 23 | Nasopharynx | 18 | 57% | 2 | Generalized | y | n | n | y | y | High |
| 16 | M | 44 | Nasal cavity | 0 | 0% | 2 | Generalized | y | n | n | y | y | High |
| 17*** | M | 36 | Nasal cavity | 43 | 47% | 1 | Generalized | y | n | n | y | y | Normal*** |
| 18*** | M | 36 | Eyelid/orbital fat | 53 | 81% | 2 | Generalized | y | n | n | y | y | *** |
| 19 | F | 64 | Nasal cavity | 8 | 13% | 2 | Generalized | y | y | n | n | n | High |
| 20 | F | 13 | Orbit | 15 | 30% | 1 | Generalized | y | y | n | n | n | Normal |
| 21 | F | 23 | Orbital mass | 69 | 83% | 3 | Generalized | y | n | n | y | y | Normal |
| 22 | F | 71 | Periorbital | 139 | 82% | 1 | Generalized | y | y | y | n | n | High |
| 23 | F | 31 | Nasal cavity | 55 | 73% | 1 | Generalized | y | n | n | y | y | High |
| 24 | F | 69 | Dura parietooccipital | 5 | 10% | 2 | Generalized | y | y | n | n | n | High |
| 25 | F | 40 | Pleura | 9 | 34% | 3 | Generalized | y | n | n | y | y | NA |
| 26 | F | 49 | Sinonasal | 37 | 44% | 1 | Limited | y | n | n | y | y | High |
*, **, *** denote the same patients. Dx: diagnosis; Path: pathology; ACR: American College of Rheumatology; ANCA: antineutrophil cytoplasmic antibody; PR3: proteinase 3; MPO: myeloperoxidase; NA: not available; CRP: c-reactive protein.
Figure 2Parenchymal necrosis with palisading granuloma, necrotizing vasculitis, and mixed inflammatory infiltrates, characteristic of GPA (hematoxylin and eosin, 100x original magnification).